Structure Therapeutics Inc. Sponsored ADR GPCR
35.93
(0.09)
(0.25%)
as of 25 Sep
- Market cap
- $2.6B
- P/E
- 0.0×
Follow GPCR
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|
Current Ratio |
12.64 | 12.62 | 7.16 | 19.14 | 24.74 | 24.81 |
Net Debt/EBITDA |
2.34 | 2.86 | 1.71 | 4.56 | 5.62 | 8.27 |
Debt/Assets |
0.72% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.89 | 0.73 | 0.87 | 0.89 | 0.95 | 1.57 |
Capex/Depreciation |
0.00 | (8.26) | 0.25 | (6.86) | (1.30) | (2.15) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 0.00% | 100.37% | 58.75% | (53.06%) | (18.60%) | (11.86%) | |
| 0.00% | (58.41%) | (50.56%) | (30.91%) | (17.69%) | (11.35%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (157.24%) |
Return on Tangible Assets |
(45.06%) | (43.00%) | (65.14%) | (19.82%) | (14.27%) | (9.33%) |
Average Days of Receivables |
— | — | — | — | — | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(0.39) | (12.29) | (14.48) | (2.22) | (2.24) | (3.81) |
Cash per Share |
1.02 | 39.54 | 28.43 | 12.72 | 16.78 | 24.43 |
Shareholders Equity per Share |
0.97 | 37.67 | 26.55 | 12.33 | 16.43 | 25.61 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.97 | 37.67 | 26.55 | 12.33 | 16.43 | 25.61 |
Free Cash Flow |
(14.31) | (33.37) | (46.27) | (81.65) | (117.93) | (225.81) |
Working Capital |
35.38 | 100.59 | 80.08 | 448.87 | 855.19 | 1,507.02 |
Capital Expenditures |
(0.02) | (1.21) | (0.15) | (2.17) | (1.29) | (3.61) |
Net Current Asset Value |
35.25 | 100.32 | 80.08 | 444.56 | 852.72 | 1,502.76 |
| Other line items | ||||||
Quick Ratio |
12.32 | 12.39 | 6.98 | 18.89 | 24.53 | 24.43 |
Depreciation/Fixed assets |
0.07 | 0.12 | (0.61) | 0.10 | 0.29 | 0.25 |
Cash ROIC |
(19.91%) | (15.91%) | (26.84%) | (8.99%) | (6.87%) | (7.72%) |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
27,867.75 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.39) | (11.85) | (14.44) | (2.16) | (2.22) | (3.75) |
Capex per Share |
0.00 | (0.44) | (0.05) | (0.06) | (0.02) | (0.06) |
Average Payables |
— | 2.51 | 4.75 | 5.38 | 6.38 | 10.94 |
Average Assets |
— | 74.93 | 104.50 | 289.93 | 692.67 | 1,243.62 |
Average Common Equity |
— | (43.60) | (89.94) | 168.91 | 658.90 | 1,190.61 |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates